ConductScience.org, home

Paper36924778

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

Lederman S and 10 others. Lancet, 2023. Cited by 199 papers, by iCite.

Cite this record

ConductScience Library. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Papers, record 36924778. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924778

Download JSON
Disease
Hot flashes47 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
PubMed
Journal
Lancet
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article
PubMed
Citations, by iCite
199
iCite
Relative citation ratio, by iCite
26.2
iCite
Revised in PubMed
2026-01-27
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lederman SSamuel
2Ottery FDFaith D
3Cano AAntonio
4Santoro NNanette
5Shapiro MMarla
6Stute PPetra
7Thurston RCRebecca C
8English MMarci
9Franklin CCatherine
10Lee MMisun
11Neal-Perry GGenevieve

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Neurokinin-3Major topic
Quality of LifeMajor topic
Humans
Female
Treatment Outcome
Menopause
Double-Blind Method
Heterocyclic Compounds, 2-Ring
Thiadiazoles

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04003155A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through MenopauseDerived from the trialYesClinicalTrials.gov
NCT06957691Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation TherapyBackgroundClinicalTrials.gov
NCT07042516Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36924777Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.https://conductscience.org/library/papers/36924777

Source PubMed

Download CSV of comments and corrections

Cited by92

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 199 citations.

PMIDTitleJournalYearIn PapersSource
42902266Efficacy and safety of non-hormonal pharmacotherapies for depressive and anxiety symptoms during the menopausal transition and postmenopause: a systematic review.BMC Psychiatry2026https://conductscience.org/library/papers/42902266PubMed
42888352Population pharmacokinetic-pharmacodynamic modeling and dose selection of GS1-144 based on luteinizing hormone suppression in postmenopausal women.J Pharmacokinet Pharmacodyn2026https://conductscience.org/library/papers/42888352PubMed
42862303
[Perimenopause and postmenopause: acute diagnostic and therapeutic aspects for the DACH region : Consensus paper of the Austrian Society for Gynecology and Obstetrics (OEGGG), the German Society for Gynecology and Obstetrics (DGGG), the German Menopause Society (DMG) and the Swiss Society for Gynecology and Obstetrics (SGGG)].
Wien Klin Wochenschr2026https://conductscience.org/library/papers/42862303PubMed
42831287NK2R signaling governs intestinal lipid mobilization and mucosal inflammation.Elife2026https://conductscience.org/library/papers/42831287PubMed
42681820Microvascular endothelial function is blunted in postmenopausal females with frequent hot flushes.Exp Physiol2026https://conductscience.org/library/papers/42681820PubMed
42654471Vasomotor Symptoms and Their Association with Depressive and Anxiety Symptoms in Peri- and Postmenopausal Women: A Systematic Review of Observational Studies.Medicina (Kaunas)2026https://conductscience.org/library/papers/42654471PubMed
42609071Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper.Int J Gynaecol Obstet2026https://conductscience.org/library/papers/42609071PubMed
42603995Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021.Gynecol Oncol Rep2026https://conductscience.org/library/papers/42603995PubMed
42580842Role of menopause in the development of cardiovascular disease in women.Open Heart2026https://conductscience.org/library/papers/42580842PubMed
42575966Menopause and neurological disorders: a roadmap for research.Nat Rev Neurol2026https://conductscience.org/library/papers/42575966PubMed
42519421A brain-first framework for perimenopause management: the case for non-invasive neuromodulation.Front Glob Womens Health2026https://conductscience.org/library/papers/42519421PubMed
42458154Women's Treatment Preferences for Moderate to Severe Vasomotor Symptoms Associated with Menopause: Insights from the WARMER Study.Patient2026https://conductscience.org/library/papers/42458154PubMed
42326829TACR3 variant confers resilience to aging and Alzheimer's disease.medRxiv2026https://conductscience.org/library/papers/42326829PubMed
42171669Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).J Endocrinol Invest2026https://conductscience.org/library/papers/42171669PubMed
42160911Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant.Breast2026https://conductscience.org/library/papers/42160911PubMed
42137787Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.J Endocr Soc2026https://conductscience.org/library/papers/42137787PubMed
42115840Flushing: Neuroendocrine Mechanisms and a Structured Diagnostic Approach.Clin Endocrinol (Oxf)2026https://conductscience.org/library/papers/42115840PubMed
41998196The effect of acupuncture on hot flashes and sleep disturbances in women with breast cancer receiving endocrine therapy: a pre-post quasi-interventional study.Support Care Cancer2026https://conductscience.org/library/papers/41998196PubMed
41981275Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation.Nat Rev Endocrinol2026https://conductscience.org/library/papers/41981275PubMed
41979542
Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.
Menopause2026https://conductscience.org/library/papers/41979542PubMed

See all 92 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
FEZOLINETANTCHEMBL3608680Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3608680

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36924778

GET https://conductscience.org/api/papers/v1/36924778/cited_by?page=2